luvadaxistat

Luvadaxistat is an investigational, orally active, highly selective and potent small molecule inhibitor of d-amino acid oxidase (DAAO). By inhibiting DAAO, luvadaxistat increases levels of D-serine, a coagonist at the N-methyl-D-aspartate receptor (NMDAR), thereby modulating NMDA receptor function in the brain. This mechanism is relevant to conditions such as schizophrenia, where NMDA receptor hypofunction is implicated in cognitive impairment. Luvadaxistat was originally developed by Takeda and later acquired for further development by Neurocrine Biosciences. It has been studied primarily for cognitive impairment associated with schizophrenia and previously for Friedreich's ataxia; however, development for Friedreich's ataxia has been discontinued[3][5][6][7][8][9].

Other names

luvadaxistat [USAN]76IC00YRVRUNII-76IC00YRVRUNII76IC00YRVRUNII 76IC00YRVR